CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 288,266	$ 453,932
Accounts receivable, net of allowance of $12,585 in 2024 and $9,501 in 2023	473,575	457,445
Inventories	381,877	380,282
Other current assets	256,179	203,595
Total current assets	1,399,897	1,495,254
Long-Term Assets:
Property and equipment, net	713,123	702,177
Operating lease right-of-use assets	116,129	115,499
Goodwill	405,100	365,961
Intangible assets, net	111,676	84,500
Other long-term assets	547,518	496,534
Total long-term assets	1,893,546	1,764,671
TOTAL ASSETS	3,293,443	3,259,925
Current Liabilities:
Accounts payable	114,211	110,643
Accrued liabilities	502,119	478,712
Credit facility	250,000	250,000
Current portion of long-term debt	167,787	74,997
Current portion of deferred revenue	33,799	37,195
Total current liabilities	1,067,916	951,547
Long-Term Liabilities:
Deferred income tax liabilities	11,312	7,235
Long-term debt, net of current portion	449,786	622,883
Long-term deferred revenue, net of current portion	26,939	28,533
Long-term operating lease liabilities, net of current portion	97,836	99,671
Other long-term liabilities	44,341	65,526
Total long-term liabilities	630,214	823,848
Total liabilities	1,698,130	1,775,395
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,836 shares in 2024 and 107,506 shares in 2023; Outstanding: 81,604 shares in 2024 and 83,032 shares in 2023	10,784	10,751
Additional paid-in capital	1,673,863	1,569,565
Deferred stock units: Outstanding: 60 units in 2024 and 59 units in 2023	5,885	5,530
Retained earnings	5,332,438	4,444,571
Accumulated other comprehensive loss	(93,645)	(71,206)
Treasury stock, at cost: 26,232 shares in 2024 and 24,474 shares in 2023	(5,334,012)	(4,474,681)
Total IDEXX Laboratories, Inc. stockholders’ equity	1,595,313	1,484,530
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 3,293,443	$ 3,259,925